MedDataX Logo

Safety and Performance of LeadExx LC System in Lead Extraction

NCT ID: NCT02996929

Last Updated: 2016-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-28

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study's main purpose is to evaluate the safety and performance of the LeadExx LC System and its ability to safely extract leads.

The study will enroll 10 patients scheduled for CIED lead extraction. The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The use of implantable cardiac devices has been exponentially increasing, and lead extraction has become a necessary procedure. But lead extraction has potentially serious complications, including venous or myocardial tear, cardiac tamponade, and even death. Powered sheaths, such as Excimer laser or a radiofrequency system, have been used for extraction of ICD or pacemaker leads. However, the Heart Rhythm Society (HRS) has stated that "possible predictors of major complications were implant duration of the oldest lead, female gender, ICD lead removal, and use of the laser extraction technique, multiple leads, and calcified leads".

To reduce the risk of the lead extraction procedure and therefore reduce the number of abandoned leads, LeadExx had developed its system.

The LC system is an active disposable system provided sterile for single use. The system is comprised of the following two main parts:

a. Dilation Unit (DU) - (invasive, sterile) b. Control Unit- (CU) - (non-invasive, sterile fluid path) The physical connection between the units is achieved by 3 Luer locks that connect the CU Solenoids' output to 3 flexible tubes at the proximal end of the DU.

1. Dilation Unit (DU):

The dilation unit is an invasive sterile unit, comprised of a dilation tip and a connecting shaft. The unit is activated using a hydraulic mechanism.

The dilation tip is threaded over the lead, inserted into the vessel together with its connecting shaft and while advancing along the lead, dilates the surrounding tissue and ultimately enables the lead removal from the vein.
2. Control Unit (CU):

The Control Unit is a non-invasive fluid path sterile unit, comprised of various off the shelf modules . The unit is being filled with sterile Saline just prior to its operation and by synchronizing the transfer of the Saline into the DU controls its advancement. I

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Implant Site Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Subjects who are scheduled for CIED lead extraction with the LC system

Group Type EXPERIMENTAL

LC System

Intervention Type DEVICE

Subjects will undergo CIED lead extraction with the LC system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LC System

Subjects will undergo CIED lead extraction with the LC system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female 18-75 years old.
2. Scheduled for an CIED lead extraction upon current guidelines
3. Willing and able to sign the informed consent.
4. Lead implant duration more than 1 year and less than 5 years.
5. Patient with Lead size 7F
6. BMI 22-32
7. Number of implanted leads 1-3

Exclusion Criteria

1. Lead implant duration is less than 1 year or more than 5 years.
2. Patients with acute and chronic lead infections
3. Pericardial or subcutaneous CIED systems (without trans venous CIED lead)
4. Pregnant or lactating.
5. Patients with expected survival of less than 1 year.
6. Subjects who are participating in another clinical study.
7. Subjects who are unable or unwilling to follow the study schedule of visits.
8. Contraindication to administration of iodinated contrast (creatinine \> 2.0 or contrast allergy)
9. Patients with a history of venous thromboembolism, coagulopathy or malignancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

LeadExx Cardiac Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eyal Nof, Dr.

Role: PRINCIPAL_INVESTIGATOR

Sheba Medical Center

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eyal Nof, Dr.

Role: CONTACT

Phone: 972-3-530-3810

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Leadexx CL-001

Identifier Type: -

Identifier Source: org_study_id